The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is branded as Mounjaro for diabetes, under a new brand for weight loss as well.While Mounjaro had already been used by some patients 'off-label' for weight loss, the new FDA approval will allow the drugmaker to begin officially selling and marketing tirzepatide — branded as Zepbound — for weight loss too.Zepbound will be available for patients in the U.S.
While there have not been results from large clinical trials comparing Novo Nordisk's and Eli Lilly's medications head-to-head, there is some research to suggest Zepboud could outperform Ozempic.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Read more »
Eli Lilly's Obesity Drug Gets FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Read more »
Eli Lilly gets FDA approval for new obesity drugZepbound helped patients lose up to 48 pounds on average in clinical trials
Read more »
FDA approves diabetes drug Zepbound to help obese patients lose weightStudies suggest Zepbound can help people lose weight with diet and exercise.
Read more »
Zepbound: FDA approves new version of diabetes drug Mounjaro for weight lossThe U.S. Food and Drug Administration on Wednesday approved a new version of the type 2 diabetes drug tirzepatide for use in chronic weight management, officials said.
Read more »